Semaglutide Benefits
-
{
- All
- News
- Videos
-
Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss
This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor.
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
Natural Ozempic, No Side Effects: Stanford Scientists Discover Peptide That Can Rival The GLP-1 Drug
One of the most fascinating aspects of this discovery is the role of artificial intelligence. Researchers developed a tool called "Peptide Predictor" to scan all human protein-coding genes.
-
Struggling To Lose Weight On Ozempic, Mounjaro? Study Says Your Genes Might Be the Hurdle
A new study reveals that your genes could be the hidden hurdle, explaining the differences in how bodies respond to weight loss drugs.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
Semaglutide Weight-Loss Drugs May Help Prevent Deadly Heart Attack Complications
Popular weight-loss drugs like semaglutide may reduce life-threatening complications after heart attacks, a UK study finds. By improving blood flow in tiny vessels, these drugs could help the heart recover, but human trials are still needed.
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
Metformin Vs Ozempic: Which Popular Diabetes Drug Improves Blood Sugar Control With Lesser Side Effects?
Metformin is usually the first-choice for the treatment of type 2 diabetes. This drug mainly works by lowering glucose production in the liver. It also helps your body respond better to insulin.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss
This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor.
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
Natural Ozempic, No Side Effects: Stanford Scientists Discover Peptide That Can Rival The GLP-1 Drug
One of the most fascinating aspects of this discovery is the role of artificial intelligence. Researchers developed a tool called "Peptide Predictor" to scan all human protein-coding genes.
-
Struggling To Lose Weight On Ozempic, Mounjaro? Study Says Your Genes Might Be the Hurdle
A new study reveals that your genes could be the hidden hurdle, explaining the differences in how bodies respond to weight loss drugs.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
Semaglutide Weight-Loss Drugs May Help Prevent Deadly Heart Attack Complications
Popular weight-loss drugs like semaglutide may reduce life-threatening complications after heart attacks, a UK study finds. By improving blood flow in tiny vessels, these drugs could help the heart recover, but human trials are still needed.
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
Metformin Vs Ozempic: Which Popular Diabetes Drug Improves Blood Sugar Control With Lesser Side Effects?
Metformin is usually the first-choice for the treatment of type 2 diabetes. This drug mainly works by lowering glucose production in the liver. It also helps your body respond better to insulin.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
